Seres Therapeutics, Inc. 8-K

What Happened
On July 8, 2026, Seres Therapeutics announced top-line results from an investigator‑sponsored trial (NCT06801067) of SER‑155 in 15 patients with moderate‑to‑severe (Grade 2–3) immune‑related enterocolitis (irEC) conducted at Memorial Sloan Kettering (PI: David Faleck, M.D.). The company said the data support continued development of SER‑155. The filing also furnished a press release and an updated corporate presentation.

Key Details

• 15 patients enrolled; participants were receiving a range of immune checkpoint inhibitors (PD‑1, PD‑L1, CTLA‑4, LAG‑3 agents and combinations).
• Primary endpoint (Day 15): 12 of 15 patients (80%) achieved an immunosuppressive‑free clinical response (≥1‑grade diarrhea improvement without systemic immunosuppressive therapy). Of those responders, 8/12 (67%) had ≥2‑grade improvement.
• Day 15 complete remission: 5 of 15 (33%) achieved immunosuppressive‑free complete clinical remission (diarrhea Grade 0).
• Day 43 durability: 5 of 15 (33%) maintained immunosuppressive‑free clinical response; 2 of 15 (13%) maintained immunosuppressive‑free complete remission. All 12 Day‑15 responders had same or better diarrhea grade at Day 43; seven received GI‑targeted (non‑systemic) immunosuppressives after Day 15.
• Safety and biomarkers: SER‑155 was generally well tolerated through Day 43 with no related serious adverse events or bloodstream infections reported; four moderate, resolved adverse events possibly related to vancomycin and SER‑155 were noted. Robust bacterial strain engraftment was observed; fecal calprotectin and fecal albumin decreased with statistically significant reductions by Day 43.

Why It Matters
These early clinical signals address an unmet need: current irEC management typically requires systemic immunosuppression (corticosteroids/biologics) that can cause serious side effects and may interrupt life‑saving cancer immunotherapy. The reported efficacy, tolerability, engraftment data, and biomarker improvements support further development of SER‑155 as a potential non‑systemic approach to reduce gastrointestinal inflammation and diarrhea in patients on immune checkpoint inhibitors. The 8‑K also includes standard forward‑looking risk disclosures about future development, funding and regulatory uncertainties.